65,437 trials
Cocaine-Related Disorders
Primary: Cocaine Use as Assessed by Proportion of Visits (Excluding Excused Absences) With Cocaine-negative Urine Drug Screen — 0.31; 0.24 proportion of visits
Behavior, Social · Psychology, Social · Social Interaction
Primary: Change in Prefrontal Cortex Brain Activity Assessed by fMRI — -0.002; 0.015 Percent BOLD Signal Change
Hemophilia
Primary: Estimated Annualized Bleeding Rate (ABR) — 7.482; 2.908 episodes per participant per year — p==0.0008
Myopia
Primary: Subjective Ratings of Lens Handling for Insertion Per Intervention — 85; 80; 75; 85 score on a scale — p=0.331
Visual Acuity
Primary: Overall Quality of Vision Score — 67.0; 70.4 Units on a scale
Infant, Newborn · Infant, Small for Gestational Age · Infant, Extremely Low Birth Weight
Primary: Bayley Scales of Infant Development (BSID) Cognitive Composite Score — 80.7; 81.1 Score on a scale
Mental Health Wellness 1 · Depression
Primary: Depression — 13.3 score on a scale
Hidradenitis Suppurativa (HS)
Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 23.8; 38.3 percentage of participants — p=0.018
Rheumatoid Arthritis
Primary: CDAI Score — 36.06 score on a scale
Non-Small-Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) by Blinded Independent Centralized Review (BICR) — 5.59; 1.54; 5.45 Months — p=0.0528
Covid19 · SARS-CoV Infection
Primary: Number of Participants With an Emergency Room Visit or Hospitalization, or Death by Day 28 — 21; 16 Participants
Low Risk Acute Graft-versus-host Disease · Graft-versus-host-disease · GVHD
Primary: Number of Patients Who Achieve CR or PR by Day 28 of Treatment — 62 Participants
Alzheimer's Disease · Disruptive Behavior
Primary: ADCS-Clinical Global Impression of Change in Agitation (ADCS-CGIC-A) — 3.434; 3.442 score on a scale — p=0.9904
Autosomal Dominant Polycystic Kidney · ADPKD
Primary: Change From Baseline in Height Adjusted Total Kidney Volume (htTKV) at Month 12 — 0.0236; 0.0288 milliliters per meter — p=0.5265
Hepatocellular Carcinoma
Primary: Phase Ib: Patients With Event(s) of Dose-limiting Toxicity — 0; 0 Participants